OSLO, Norway, May 30, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the company's Annual General Meeting on 30 May 2018.
Mr Boehm is an oncology expert with nearly 30 years' product development, commercial and
During his tenure at Novartis, Mr Boehm oversaw the commercial launches of various oncology brands in the US and globally including Femara®, Zometa®, Glivec®, among others.
Mr Boehm is a member of the Board of Directors at Cellectis SA and Humanigen Inc.
He has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.
Ludvik Sandnes, Chairman of Nordic Nanovector, comments: "The Board is very pleased to welcome Rainer as a member. We are sure that his extensive experience in oncology and commercialisation will be invaluable with regards to the future development of the Company."
Rainer Boehm added: "I am excited to join the Board and provide strategic input as the Company progresses its lead candidate through clinical development towards commercialisation. Betalutin® could provide an important treatment option for non-Hodgkin's lymphoma patients and I look forward to working with the Board and the management through this important stage of development for the Company."
For further information, please contact: Malene Brondberg, VP, Investor Relations and Corporate Communications Tel/Cell: + 44-7561-431-762 Email: firstname.lastname@example.org
Media enquiries: Mark SwallowDavid DibleIsabelle Andrews (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: email@example.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector--rainer-boehm-md-elected-to-board-of-directors-300656378.html
SOURCE Nordic Nanovector
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All